CRISPR THERAPEUTICS AG (CRSP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 132.90M USD | Liabilities, Current |
| Cash and equivalents | 291.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.07B USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $132.90M | $291.34M | $2.07B | (m) | (m) | (m) |
| 2026-03-31 | (m) | $136.29M | $423.31M | $2.02B | (m) | (m) | (m) |
| 2025-12-31 | $1.98B | $149.12M | $347.56M | $1.63B | $0.00 | (m) | 13.25× |
| 2025-09-30 | $1.92B | $118.96M | $286.50M | $1.63B | $0.00 | (m) | 16.10× |
| 2025-06-30 | $1.72B | $104.36M | $193.62M | $1.53B | $0.00 | (m) | 16.49× |
| 2025-03-31 | $1.86B | $119.45M | $235.18M | $1.62B | $0.00 | (m) | 15.53× |
| 2024-12-31 | $1.93B | $87.78M | $298.26M | $1.61B | $25.00M | (m) | 21.97× |
| 2024-09-30 | $1.94B | $89.81M | $225.67M | $1.71B | $0.00 | (m) | 21.55× |
| 2024-06-30 | $2.00B | $127.82M | $484.47M | $1.52B | $0.00 | (m) | 15.66× |
| 2024-03-31 | $2.11B | $118.99M | $707.43M | $1.40B | $0.00 | (m) | 17.72× |
| 2023-12-31 | $1.89B | $108.79M | $389.48M | $1.30B | $200.00M | (m) | 17.41× |
| 2023-09-30 | (m) | $111.23M | $527.76M | $1.21B | (m) | (m) | (m) |
| 2023-06-30 | $1.84B | $132.84M | $444.80M | $1.32B | $70.00M | (m) | 13.84× |
| 2023-03-31 | (m) | $146.79M | $344.41M | $1.54B | (m) | (m) | (m) |
| 2022-12-31 | $1.82B | $121.11M | $211.88M | $1.60B | $0.00 | (m) | 14.99× |
| 2022-09-30 | $1.90B | $150.87M | $494.15M | $1.40B | $49.00K | (m) | 12.57× |
| 2022-06-30 | $2.07B | $119.96M | $496.89M | $1.57B | $66.00K | (m) | 17.22× |
| 2022-03-31 | $2.22B | $113.70M | $683.91M | $1.54B | $143.00K | (m) | 19.54× |
| 2021-12-31 | $2.38B | $119.88M | $923.03M | $1.46B | $305.00K | (m) | 19.85× |
| 2021-09-30 | $2.48B | $96.21M | $1.01B | $1.47B | $152.00K | (m) | 25.75× |
| 2021-06-30 | $2.59B | $99.92M | $1.65B | $942.80M | $150.00K | (m) | 25.92× |
| 2021-03-31 | $1.81B | $83.09M | $1.13B | $680.14M | $150.00K | (m) | 21.74× |
| 2020-12-31 | $1.69B | $94.26M | $1.17B | $521.71M | $144.00K | (m) | 17.93× |
| 2020-09-30 | $1.37B | $84.15M | $1.04B | $324.57M | $110.00K | (m) | 16.23× |
| 2020-06-30 | (m) | $74.50M | $945.07M | (m) | $33.00K | (m) | (m) |
| 2020-03-31 | (m) | $55.09M | $889.71M | (m) | $25.12M | (m) | (m) |
| 2019-12-31 | (m) | $57.11M | $943.77M | (m) | $99.00K | (m) | (m) |
| 2019-09-30 | (m) | $79.78M | $629.72M | (m) | $39.00K | (m) | (m) |
| 2019-06-30 | (m) | $31.41M | $427.88M | (m) | $321.00K | (m) | (m) |
| 2019-03-31 | (m) | $28.40M | $437.55M | (m) | $331.00K | (m) | (m) |
| 2018-12-31 | (m) | $27.75M | $456.65M | (m) | $88.00K | (m) | (m) |
| 2018-09-30 | (m) | $32.28M | (m) | (m) | $552.00K | (m) | (m) |
| 2018-06-30 | (m) | $18.48M | (m) | (m) | $944.00K | (m) | (m) |
| 2018-03-31 | (m) | $14.39M | (m) | (m) | $1.26M | (m) | (m) |
| 2017-12-31 | (m) | $14.51M | $239.76M | (m) | $2.63M | (m) | (m) |
| 2017-09-30 | (m) | $12.12M | $253.52M | (m) | $3.21M | (m) | (m) |
| 2017-06-30 | (m) | $15.81M | $272.26M | (m) | $6.81M | (m) | (m) |
| 2017-03-31 | (m) | $16.91M | $288.87M | (m) | $5.67M | (m) | (m) |
| 2016-12-31 | (m) | $22.00M | $315.52M | (m) | $3.16M | (m) | (m) |
| 2016-09-30 | (m) | $78.10M | $228.61M | (m) | $2.09M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $246.85M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $200.60M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $10.15M | $155.96M | (m) | $339.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | $49.05M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $945.00K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $361.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |